A European study finds hospitalisations and insufficient growth reduce health-related quality of life in childhood ...

By Sahil Pandey and Siddhi Mahatole Feb 23 (Reuters) - Gossamer Bio's experimental treatment failed to significantly improve ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

Authorities have not confirmed the cause of death, but said samples showed canine distemper virus.

Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness ...

If you’ve noticed you’re getting winded faster, wheezing or coughing more, doctors say, don’t ignore it. Chronic obstructive ...

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...

Feb 23 (Reuters) - Gossamer Bio said on Monday its experimental drug for patients with a type of lung condition missed the ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

After a 3-hour flight, however, he developed dyspnea and leg edema, and CT pulmonary angiography confirmed acute PE. He was started on rivaroxaban (Xarelto); but while taking it, he experienced ...